thx
Seite 1 von 1 Neuester Beitrag: 11.08.03 21:54 | ||||
| Eröffnet am: | 05.08.03 02:54 | von: QADSAN | Anzahl Beiträge: | 8 |
| Neuester Beitrag: | 11.08.03 21:54 | von: Eskimato | Leser gesamt: | 1.377 |
| Forum: | Hot-Stocks | Leser heute: | 1 | |
| Bewertet mit: |  | |||
Ein weiter Pinksheets den man beobachten sollte ist DVPC! man beachte die letzte News mit Schlumbeger!
Es ist nicht alles Gold was glänzt aber es ist auch nicht alles Shit was Pink ist!
XINGE hat heute das Filing abgegeben, darum der nachbörsliche Anstieg. Erwarte morgen noch mehr!
Mein Depot bleibt unverändert!
Grüße an die Mitspieler!
QADSAN
OT: Tournigan Gold wird auch noch kommen! :-) aber heftig
Es gibt so viele Shares, kann man alle gar nicht vorstellen.
Son paar Explorer beobachte ich auch, MEXP z.B., viele bekanntere Goldminen.
BGO hatte sich Reinyboy zu 1,05 mal reingelegt, war nen gutes Timing.
Bei den kanadischen Explorern haperts bei mir mit der Kurslieferung, da halte ich mich raus, obwohl ich ständig E-Mails bekomme vom Oberbayerischen Börsenbrief, ausgewiesene Kenner meiner Meinung nach, die empfehlen Tournigan auch schon länger und Donner Minerals und andere kanadische Explorer.
Alle kann und brauch man nicht kennen, DVPC schau ich mir aber mal an. An Pinks beobachte ich noch REGI, Viragen und Whole Living.
So long, will ich doch gar nicht ignorieren, wer treibt sich denn sonst noch um diese Uhrzeit im Forum rum?
Da braucht man nicht jedes Wort auf die Goldwaage legen, bin jetzt aber müde und verschwunden.
Gruss E.
Meine angesprochenen AMDL heute mit neuem 52-Wochen-Hoch und 20 % Kursgewinn, fangen an nach Australien und Neusseland zu verkaufen.
Gruss E.
AMDL's DR-70(R) Begins Sale in Australia, New Zealand
MONDAY, JULY 21, 2003 2:16 PM
- PR Newswire
TUSTIN, Calif. and VICTORIA, Australia, Jul 21, 2003 /PRNewswire-FirstCall via COMTEX/ -- AMDL, Inc. (ADL) today announced that AMDL Australia Pty. Ltd., AMDL's distributor, has begun the sale of the DR-70(R) cancer detection test in Australia and New Zealand. Australia's Therapeutic Goods Administration (TGA) previously granted approval to market DR-70(R) to the Australian company.
AMDL Australia Pty. Ltd., which is not affiliated with AMDL in the U.S., is AMDL's exclusive distributor of the DR-70(R) blood test in Australia and New Zealand. Anna-Louise Brown, Director of AMDL Australia, said, "Australia and New Zealand, with combined populations of more than 20 million, are very sophisticated countries with superior health care systems. We believe they will be an excellent marketplace for DR-70(R)."
DR-70(R) is a non-intrusive blood test that can detect and monitor 13 types of cancer from a single 2ml blood serum sample. These cancers include cervical, breast, lung, colon, liver, stomach and malignant lymphoma. Studies published in the Journal of Immunoassay determined that DR-70(R) demonstrated its ability to detect the presence of cancers in humans 84% of the time. Clinical trials of DR-70(R) have been conducted in Germany, China, Canada, Turkey and Taiwan. DR-70(R) can detect cancer using a single tube of blood, eliminating the need for costly, multiple tests.
"While we are focused on getting our product cleared to sell in the U.S. at this time, it is still crucial for AMDL to continue to find excellent potential markets overseas," said Gary L. Dreher, AMDL President. "We are confident that Australia and New Zealand will be a strong marketplace for DR-70(R)."
About AMDL:
AMDL, Inc. (ADL) , headquartered in Tustin, California, is a theranostics company, involved in both the detection and treatment of the same disease, cancer. AMDL is the inventor and developer of the DR-70(R) non-invasive cancer blood test. DR-70(R) has demonstrated its ability to detect the presence in humans of up to 13 cancers 84 percent of the time overall. Clinical trials of DR-70(R) have been conducted in Germany, China, Canada, Taiwan and Turkey. Cancers that can be detected are lung, colon, breast, stomach, liver, rectal, ovarian, cervical, esophageal, thyroid, pancreatic, trophoblastic and malignant lymphoma. DR-70(R) can detect many kinds of cancer using a single tube of blood, eliminating the need for costly, multiple tests. AMDL has recently received approval from the Health Protection Agency to market DR-70(R) in Canada. AMDL makes DR-70(R) available worldwide through exclusive distribution agreements. AMDL also owns a combination immunogene therapy technology that is a possible treatment for those already diagnosed with cancer and could eventually be used as a vaccine to protect patients known to be at risk because of a family history for certain types of cancer. The technology both builds the body's immune system and destroys cancer cells. AMDL recently contracted with the University of Florida to begin studies of breast cancer using the combination immunogene therapy technology. More information about AMDL and its additional products can be obtained at www.amdlcorporate.com .
Forward-Looking Statements
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.
SOURCE AMDL, Inc.
Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460,
or Anna-Louise Brown of AMDL Australia Pty. Ltd., 03 9762 9015,
enq@amdlaustralia.com.au
http://www.amdlcorporate.com
Da gehen auch Stückzahlen in Frankfurt um.
Gruss E.
Welcome [Sign In] To track stocks & more, Register
Financial News
Enter symbol(s) BasicDayWatchPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup
Press Release Source: Cambior Inc.
Cambior: Conference Call - Corporate Update
Friday August 8, 3:46 pm ET
LONGUEUIL, Quebec--(BUSINESS WIRE)--Aug. 8, 2003--Cambior will host a conference call on August 12, 2003 at 11:00 a.m. (local time). The Company will provide an update on the progress at the Rosebel Gold Project in Suriname and on the Company's exploration and operations activities.
Financial analysts are invited to participate in the call by dialling 1-800-470-5906 in North America. Outside of North America, please dial (416) 641-6687. Media and all other interested individuals are invited to listen to the live webcast on the Cambior website at www.cambior.com or through CCNMatthews at www.ccnmatthews.com/cambior . It will also be possible to view or download the Powerpoint presentation of the teleconference through the Company's site at www.cambior.com.
The conference call will be available for replay for a period of 48 hours by calling (416) 626-4100, reservation #21157918. The webcast will also be archived on the Company's website.
Cambior Inc. is an international gold producer with operations, development projects and exploration activities throughout the Americas. Cambior's shares trade on the Toronto (TSX) and American (AMEX) stock exchanges under the symbol "CBJ". Cambior's warrants trade on the TSX.
--------------------------------------------------